Bristol-Myers Squibb
BMY
$44.85
Share price
0.34%
Change (1 day)
-32.83%
Change (1 year)
Categories
Bristol-Myers Squibb (BMY) - Cash on Hand
Cash on Hand as of March 2024 : $9.67 B
According to Bristol-Myers Squibb's latest financial reports the company has $9.67 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Bristol-Myers Squibb - Cash on Hand chart (from 2001 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $12.28 B | 32.71% |
| 2022-12-31 | $9.25 B | -46.27% |
| 2021-12-31 | $17.22 B | 4.69% |
| 2020-12-31 | $16.45 B | 6.87% |
| 2019-12-31 | $15.39 B | 75.74% |
| 2018-12-31 | $8.75 B | 28.58% |
| 2017-12-31 | $6.81 B | 7.28% |
| 2016-12-31 | $6.35 B | 48.71% |
| 2015-12-31 | $4.27 B | -42.57% |
| 2014-12-31 | $7.43 B | 64.31% |
| 2013-12-31 | $4.52 B | 59.95% |
| 2012-12-31 | $2.82 B | -67.61% |
| 2011-12-31 | $8.73 B | 19.61% |
| 2010-12-31 | $7.30 B | -14.25% |
| 2009-12-31 | $8.51 B | 3.01% |
| 2008-12-31 | $8.26 B | 271.46% |
| 2007-12-31 | $2.22 B | -44.56% |
| 2006-12-31 | $4.01 B | -30.8% |
| 2005-12-31 | $5.79 B | -22.41% |
| 2004-12-31 | $7.47 B | 34.38% |
| 2003-12-31 | $5.56 B | 39.43% |
| 2002-12-31 | $3.98 B | -29.45% |
| 2001-12-31 | $5.65 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $22.92 B | 137.09% | 🇺🇸 USA |
 Novartis NVS | $9.69 B | 0.25% | 🇨🇭 Switzerland |
 Pfizer PFE | $12.69 B | 31.23% | 🇺🇸 USA |
 AbbVie ABBV | $12.81 B | 32.53% | 🇺🇸 USA |
 Eli Lilly LLY | $2.92 B | -69.72% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 13.17% | 🇺🇸 USA |
 Sanofi SNY | $9.92 B | 2.67% | 🇫🇷 France |
 Biogen BIIB | $1.07 B | -88.89% | 🇺🇸 USA |
 Merck MRK | $7.09 B | -26.65% | 🇺🇸 USA |
 AstraZeneca AZN | $8.02 B | -17.05% | 🇬🇧 UK |